Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line osimertinib in EGFR-mutated NSCLC
2018-001863-21Phase 2Active
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in EGFR-mutated non-small cell lung cancer, sponsored by Vestre Viken Hospital Trust. Primary endpoints: Objective response and Progression-free survival. Started Jul 2018; status: active.
02
Drugs
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2018-001863-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001863-21.